Trends in prescription of anti-seizure medicines for Japanese pediatric outpatients during 2013–2019

Kikuchi, Daisuke; Obara, Taku; Kashiwagura, Shota; Arima, Youtaro; Hino, Hiroaki; Miura, Ryosuke; Hayakawa, Shinya; Watanabe, Yoshihisa

doi:10.1016/j.ebr.2021.100474

Cited by 4 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are consistent with a recent study in patients with newly diagnosed focal epilepsy, which used the same insurance claims database between 2006 and 2017 [6]. Other studies have also shown similar trends in pediatric or adult patients with epilepsy [3,[12][13][14]. However, these trends were not apparent in the subpopulation with generalized epilepsy, possibly because of the small number of patients in this subgroup.…”

Section: Discussionsupporting

confidence: 90%

Prescription trends in anti-seizure medications for adult patients with epilepsy in Japan: A retrospective cohort study using the database of health insurance claims between 2015 and 2019

Jin

Obara

Hirano

et al. 2022

Epilepsy & Behavior

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Prescription trends in anti-seizure medications for adult patients with epilepsy in Japan: A retrospective cohort study using the database of health insurance claims between 2015 and 2019

Jin

Obara

Hirano

et al. 2022

Epilepsy & Behavior

Self Cite

View full text Add to dashboard Cite

“…Adjunctive LEV treatment stopped focal and generalized seizures, which were previously drug resistant 5–7 . LEV is commonly used for both monotherapy and polytherapy to treat a broad spectrum of seizure types 8,9 …”

Section: Introductionmentioning

confidence: 99%

“…[5][6][7] LEV is commonly used for both monotherapy and polytherapy to treat a broad spectrum of seizure types. 8,9 Adverse drug reactions (ADRs) are associated with LEV treatment. An estimated 18% of people with epilepsy treated with LEV will experience some neuropsychiatric response, resulting in dosage lowering or, more frequently, cessation of treatment.…”

Section: Introductionmentioning

confidence: 99%

A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam

et al. 2022

View full text Add to dashboard Cite

Objective: Levetiracetam (LEV) is an effective antiseizure medicine, but 10%-20% of people treated with LEV report psychiatric side-effects, and up to 1% may have psychotic episodes. Pharmacogenomic predictors of these adverse drug reactions (ADRs) have yet to be identified. We sought to determine the contribution of both common and rare genetic variation to psychiatric and behavioral ADRs associated with LEV.Methods: This case-control study compared cases of LEV-associated behavioral disorder (n = 149) or psychotic reaction (n = 37) to LEV-exposed people with no history of psychiatric ADRs (n = 920). All samples were of European ancestry. We performed genome-wide association study (GWAS) analysis comparing those with LEV ADRs to controls. We estimated the polygenic risk scores (PRS) for schizophrenia and compared cases with LEV-associated psychotic reaction to controls. Rare variant burden analysis was performed using exome sequence data of cases with psychotic reactions (n = 18) and controls (n = 122).Results: Univariate GWAS found no significant associations with either LEVassociated behavioural disorder or LEV-psychotic reaction. PRS analysis showed that cases of LEV-associated psychotic reaction had an increased PRS for schizophrenia relative to contr ols (p = .0097, estimate = .4886). The rare-variant analysis found no evidence of an increased burden of rare genetic variants in people who had experienced LEV-associated psychotic reaction relative to controls. Significance:The polygenic burden for schizophrenia is a risk factor for LEVassociated psychotic reaction. To assess the clinical utility of PRS as a predictor, it should be tested in an independent and ideally prospective cohort. Larger sample sizes are required for the identification of significant univariate common genetic signals or rare genetic signals associated with psychiatric LEV ADRs.

show abstract

Hepatotoxicity of newer antiseizure medications in children: an overview and disproportionality analysis of VigiBase

Petrović,

Kovačević,

Kovačević

et al. 2024

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

Trends in prescription of anti-seizure medicines for Japanese pediatric outpatients during 2013–2019

Cited by 4 publications

References 8 publications

Prescription trends in anti-seizure medications for adult patients with epilepsy in Japan: A retrospective cohort study using the database of health insurance claims between 2015 and 2019

Prescription trends in anti-seizure medications for adult patients with epilepsy in Japan: A retrospective cohort study using the database of health insurance claims between 2015 and 2019

A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam

Hepatotoxicity of newer antiseizure medications in children: an overview and disproportionality analysis of VigiBase

Contact Info

Product

Resources

About